Main description:

The third edition of this critically acclaimed book has updated and expanded the survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma. Internationally renowned editors and contributors explore the latest developments in molecular genetics, focusing on the novel targets that have been discovered in epithelial renal tumors.

Comprehensive and authoritative, Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Third Edition is the definitive text on the rapidly evolving landscape of experimental therapeutics, written and edited by leaders of the field.

Contents:

Table of Contents

"Renal Cell Carcinoma: Molecular Targets & Clinical Applications, 3rd Edition"

Editors: Ronald M. Bukowski, M.D., Robert Figlin, M.D., Robert Motzer, M.D.

Ch. 1: Targeted Therapy for Metastatic Renal Cell Carcinoma : the First Ten Years

Ronald M. Bukowski, M.D., Robert Figlin, M.D., Robert Motzer, M.D.

Ch. 2: RCC: Pathologic and Molecular assessment of Targets

Ferran Algaba, M.D.

Ch. 3: Targeted Therapy for Metastatic Renal Cell Carcinoma : the First Ten Years

Stephen M. Keefe, M.D., W. Kimryn Rathmell, M.D., Ph.D., Katherine L. Nathanson, M.D.

Ch. 4: VHL and HIF in clear cell Renal Cell Carcinoma: Molecular Abnormalities and Potential Clinical Applications

Lucy Gossage, M.R.C.P., M.Sc.

Ch. 5: PBRM1: A Critical Subunit of the SWI/SNF Chromatin Remodeling Complex

Chung-Han Lee, M.D., Ph.D., Can G. Pham, Ph.D., James J. Hsieh, M.D., Ph.D.

Ch. 6: Sporadic RCC - Abnormalities in Histone Modifying Genes

Ruhee Dere, Ph.D., Thai H. Ho, M.D., Ph.D.

Ch. 7: Genetic Heterogeneity in Renal Cell Carcinoma: Clinical Implications?

Susan A.J. Vaziri, Ph.D, Mahrukh K. Ganapathi, Ph.D, Ram N. Ganapathi, Ph.D.

Ch. 8: First-Generation Tyrosine Kinase Inhibitors - Clinical Results

Han Hsi Wong, Ph.D. Tim Eisen, Ph.D., F.R.C.P.

Ch. 9: Second Generation Tyrosine Kinase Inhibitors (Pazopanib) in Renal Cell Carcinoma: Current Status

Linda Cerbone, M.D., Cora N. Sternberg, M.D., F.A.C.P.

Ch. 10: Third Generation TKIs (Axitinib, Tivozanib) in RCC: enhanced efficacy and diminished toxicity?

Hui Zhu, M.D., Ph.D., Brian I. Rini, M.D. F.A.C.P.,

Ch. 11: Anti-VEGF and VEGFR monoclonal antibodies in RCC

Bernard Escudier, M.D., Laurence Albiges, M.D.

Ch. 12: PI3-Kinase, Akt, and mTOR Inhibitors in RCC

Daniel C. Cho, M.D., James W. Mier, M.D.

Ch. 13: Carbonic anhydrase IX & Monoclonal Antibody G250: relevance as a clinical and biologic target in Renal Cell Carcinoma

Egbert Oosterwijk, Ph.D., Otto C. Boerman, Ph.D., Jeannette C. Oosterwijk-Wakka, B.Sc. Wim J. Oyen, M.D., Ph.D., Peter F. A. Mulders, M.D., Ph.D.

Ch. 14: EGFR and HER2: Relevance in Renal Cell Carcinoma

Sarathi Kalra, M.D., Eric Jonasch, M.D.

Ch. 15: The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma

Fabiola Cecchi, Ph.D., Young H. Lee, Ph.D., Benedetta Peruzzi, Ph.D., Jean-Baptiste Lattouf, M.D. Donald P. Bottaro, Ph.D.

Ch. 16: Development of Resistance to Targeted Therapy: Preclinical Findings and Clinical Relevance

James W. Mier, M.D., Rupal S. Bhatt, M.D., Ph.D., David J. Panka, Ph.D., Michael B. Atkins, M.D.

Ch. 17: Development of Combination Therapy with Targeted Agents

C. Lance Cowey, M.D., Thomas E. Hutson, D.O., Pharm.D., F.A.C.P.

Ch. 18: Side Effects of Targeted Thearpy

Luis Leon, M.D., Luis Miguel Anton Aparicio, M.D., Emilio Esteban Gonzalez, M.D., Martin Lazaro Quintela, Ph.D., Sergio Vazquez Estevez, M.D.

Ch. 19: The Role of Targeted Therapy in Special Populations

James M.G. Larkin, Ph.D., F.R.C.P., Martin E. Gore, Ph.D., F.R.C.P.

Ch. 20: Immunotherapy: the Current Role of Cytokines

Mayer Fishman, M.D., Ph.D.

Ch. 21: Immune Checkpoint Inhibitors (anti-CTLA4, anti PD-1) in RCC

David F. McDermott, M.D., Alexandra Bailey, M.D.

Ch. 22: Vaccines in RCC: Clinical and Biological Relevance

Devin B. Lowe, Ph.D., James H. Finke, Ph.D., Jorge A. Garcia, Walter J. Storkus, M.D.

Ch. 23: Development and Incorporation of Biomarkers in RCC Therapeutics

Sumanta K. Pal, M.D., Robert A. Figlin, M.D.

Ch. 24: Molecularly Targeted Staging Strategies in Renal Cell Carcinoma

Steven G Koopman, M.D., Ali-Reza Sharif-Afshar, M.D., Robert A Figlin, M.D., Hyung L Kim, M.D.

Ch. 25: Clinical Prognostic Factors in Metastatic Renal Cell Carcinoma

Nimira Alimohamed M.D., Toni K. Choueiri M.D., Daniel Y.C. Heng M.D.

Ch. 26: The Role of Advocacy in Renal Cell Carcinoma

William P. Bro, B.S.B., Paul Larson, M.S.